Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00983)
Name	Dactinomycin
Synonyms	Click to Show/Hide the Synonyms of This API DACTINOMYCIN; actinomycin D; Actinomycin C1; Cosmegen; Actinomycin IV; 50-76-0; Meractinomycin; ActD; ACT D; Dactinomycine [INN-French]; Dactinomycinum [INN-Latin]; UNII-1CC1JFE158; Dactinomicina [INN-Spanish]; Lyovac cosmegen; Dactinomycin D; Oncostatin K; Chounghwamycin B; Actinomycin 7; NCI-C04682; MFCD00005033; Actinomycin Aiv; Actinomycin I; GNF-Pf-2290; MLS001424196; 1CC1JFE158; Actinomycin I1; CHEBI:27666; Actinomycin X 1; Actinomycin A IV; Acto-D; Dilactone actinomycin D acid; Actactinomycin A IV; Actinomycin C(sub1); Dilactone actinomycindioic D acid; NCGC00161622-02; Actinomycin I(sub 1); SMR000469227; DSSTox_CID_31; Actinomycin 11 cosmegen; Cosmegen Lyovac; Lyovac-Cosmegen; CCRIS 9; DSSTox_RID_75330; DSSTox_GSID_20031; 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide; HSDB 3220; Dactinomicina; Dactinomycine; Dactinomycinum; Actinomycindioic D acid, dilactone; Antibiotic from Streptomyces parvullus; Actinomycin-(threo-val-pro-sar-meval); ACTINOMYCIN-D; CAS-50-76-0; ACT [antibiotic]; X 97; 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide; 2-amino-N1,N9-bis((6S,9R,10S,13R,18aS)-6,13-diisopropyl-2,5,9-trimethyl-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1]oxa[4,7,10,13]tetraazacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide; AD (VAN); GNF-PF-1977; NSC3053; NSC-3053; Glycopeptide, 4a; 2-amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamide; NSC 3053; Dactinomycin [USAN:USP:INN:BAN]; EINECS 200-063-6; AI3-26374; UPCMLD-DP055; SCHEMBL3844; CHEMBL1554; cid_457193; DTXSID9020031; UPCMLD-DP055:001; UPCMLD-DP055:002; BDBM43866; HMS2052O17; Tox21_111997; Tox21_202482; BDBM50089528; s8964; AKOS030228553; Tox21_111997_1; CCG-101134; DB00970; NC00384; NCGC00090796-01; NCGC00161622-01; NCGC00260031-01; NCGC00271789-02; 3H-Phenoxazine-1,9-dicarboxamide, 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-; BP-25384; Specific stereoisomer of N,N'-((2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-diyl)-bis(carbonylimino(2-hydroxypropylidene)carbonyliminoisobutylidenecarbonyl-1,2-pyrrolidinediylcarbonyl(methylimino)methylenecarbonyl))bis(N-methyl-L-valine) dilactone; Stereoisomer of N,N'-((2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-diyl)bis(carbonylimino(2-(1-hydroxyethyl)-1-oxo-2,1-ethanediyl)imino(2-(1-methylethyl)-1-oxo-2,1-ethanediyl)-1,2-pyrrolidinediylcarbonyl(methylimino) (1-oxo-2,1-ethanediyl)))bis(N-methyl-L-valine)di-xi-lactone; 15160-EP2272827A1; 15160-EP2275420A1; 15160-EP2280012A2; 15160-EP2281815A1; 15160-EP2289892A1; 15160-EP2292615A1; 15160-EP2295055A2; 15160-EP2295416A2; 15160-EP2295426A1; 15160-EP2295427A1; 15160-EP2298748A2; 15160-EP2298764A1; 15160-EP2298765A1; 15160-EP2301928A1; 15160-EP2301933A1; 15160-EP2305640A2; 15160-EP2305642A2; 15160-EP2305671A1; 15160-EP2308833A2; 15160-EP2311453A1; 15160-EP2311808A1; 15160-EP2311827A1; 15160-EP2311829A1; 15160-EP2311842A2; 15160-EP2316832A1; 15160-EP2316833A1; AB00514445-05; 050A760; Q186127; SR-01000763161; SR-01000763161-4; Actinomycin D, from Streptomyces sp., >=95% (HPLC); Actinomycin D, from Streptomyces sp., ~98% (HPLC); BRD-K70578146-001-01-8; BRD-K70578146-001-04-2; UNII-0OCC969V50 component RJURFGZVJUQBHK-IIXSONLDSA-N; Dactinomycin, United States Pharmacopeia (USP) Reference Standard; Actinomycin D, for fluorescence, >=90% (HPLC), from Streptomyces sp.; Actinomycin D, from Streptomyces sp., suitable for cell culture, >=95%; 1-N,9-N-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1H-pyrrolo[2,1-i]1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl]-2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide; 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis-[(18aS)-10c,14,17-trimethyl-5,8,12,15,18-pentaoxo-6c,13t-di(propan-2-yl)-18ar-hexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-9c-yl]-3H-phenoxazine-1,9-dicarboxamide; 2-amino-4,6-dimethyl-3-oxo-N1,N9-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide; 2-amino-N,N''''''''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide; 2-amino-N,N''''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide; 2-amino-N,N''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide; 2-amino-N1,N9-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-phenoxazine-1,9-dicarboxamide; 2-azanyl-4,6-dimethyl-3-oxidanylidene-N1,N9-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentakis(oxidanylidene)-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
Clinical Status	Approved
PubChem CID	457193
Formula	C62H86N12O16
Canonical SMILES	C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C
InChI	1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1
InChIKey	RJURFGZVJUQBHK-IIXSONLDSA-N
	Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure	<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=457193"></iframe>
Structure	3D MOL is unavailable		2D MOL
Physicochemical Properties	Molecular Weight	1255.4	Topological Polar Surface Area	356
	XlogP	3.8	Complexity	3030
	Heavy Atom Count	90	Rotatable Bond Count	8
	Hydrogen Bond Donor Count	5	Hydrogen Bond Acceptor Count	18

Full List of Drug Formulations (DFMs) Containing This API
Dactinomycin 0.5mg/1ml lyophilized powder			Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s)
Drug Formulation 1	DFM Info click to show the detail info of this DFM
All DIGs	Click to Show/Hide the Full List of DIGs in This DFM Mannitol; Water
Dosage Form	Lyophilized Powder
Company	Meitheal Pharmaceuticals
DIG(s) with Biological Activity
	DIG Name	DIG Info	Representative Biological Activity of This DIG	REF
	Mannitol	DIG Info	Glycine receptor alpha-1 (EC50 = 12589.25 nM)	[1]
Drug Formulation 2	DFM Info click to show the detail info of this DFM
All DIGs	Click to Show/Hide the Full List of DIGs in This DFM Mannitol
Dosage Form	Lyophilized Powder
Company	Mylan Institutional ; Recordati Rare Diseases
DIG(s) with Biological Activity
	DIG Name	DIG Info	Representative Biological Activity of This DIG	REF
	Mannitol	DIG Info	Glycine receptor alpha-1 (EC50 = 12589.25 nM)	[1]

References
1	Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorg Med Chem Lett. 2017 Jun 1; 27(11):2239-2258.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.